SLC5A2 and diabetic kidney disease: Recent studies suggested HIF-1α could be a therapeutic target of SGLT2 inhibitors in DKD, and multiple molecular mechanisms were investigated but still unclear (Bessho et al., 2019; Cai et al., 2020; Li et al., 2020).